Currently out of the existing stock ratings of Dominic Lunn, 7 are a HOLD (53.85%), 3 are a SELL (23.08%), 3 are a BUY (23.08%).

Dominic Lunn

Work Performance Price Targets & Ratings Chart

Analyst Dominic Lunn, currently employed at CREDIT SUISSE, carries an average stock price target met ratio of 40% that have a potential upside of 5.31% achieved within 59 days.

Dominic Lunn’s has documented 25 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NVO, Novo Nordisk A/S at 03-Nov-2022.

Wall Street Analyst Dominic Lunn

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 8/23/2021. The price target of $49.37 was fulfilled within 8 days with a profit of $2.31 (4.47%) receiving and performance score of 5.59.

Average potential price target upside

GSK GlaxoSmithKline PLC ADR NVO Novo Nordisk A/S NVS Novartis AG ADR AZN AstraZeneca PLC ADR SNY Sanofi ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

1 months 5 days ago
(15-Nov-2024)

0/13 (0%)

$-19.36 (-47.20%)

Buy

$39.5

$5.55 (16.35%)

$53

1 months 8 days ago
(12-Nov-2024)

2/5 (40%)

$4 (11.27%)

368

Buy

$22.07

5 months 12 days ago
(08-Jul-2024)

0/14 (0%)

$-16.41 (-42.65%)

Hold

$44

$10.05 (29.60%)

$18.72

10 months 27 days ago
(23-Jan-2024)

1/14 (7.14%)

$5.42 (14.05%)

107

Hold

$19.52

$-14.43 (-42.50%)

$18.9

1 years 4 months 6 days ago
(14-Aug-2023)

0/3 (0%)

$-14.59 (-42.77%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Dominic Lunn?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?